A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2004
12/02/2004	US20040242511 Method
12/02/2004	US20040242505 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
12/02/2004	US20040242504 Novel composition and method for the treatment of hypertension
12/02/2004	US20040242503 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease
12/02/2004	US20040242501 Spermicidal and virucidal properties of various forms of sophorolipids
12/02/2004	US20040242491 For use in the treatment of gout and related symptoms or in the amelioration of symptoms related to a high level of uric acid such as muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, or as a dietary supplement
12/02/2004	US20040242480 Method for treating coumarin-induced hemorrhage
12/02/2004	US20040242472 Use of artemin, a member of the gdnf ligand family
12/02/2004	US20040242459 Method for treating inflammatory diseases by administering a ppar-delta agonist
12/02/2004	US20040242457 Use of anti-glaucoma drugs to treat visual defects associated with the use of a GABAergic agent
12/02/2004	US20040242452 For effecting mental control through psycho-sedation or psycho-stimulation
12/02/2004	US20040241826 Mycobacterial antigens expressed during latency
12/02/2004	US20040241818 Assay
12/02/2004	US20040241792 Substrates and assays for beta-secretase
12/02/2004	US20040241694 Using expression patter of neurodegenerative marker to diagnose/prognose brain disorders
12/02/2004	US20040241682 Cancer
12/02/2004	US20040241640 Internalisation of virus into cells
12/02/2004	US20040241248 Crosslinking the carboxylic acid groups in a glycosaiminoglycan with a primary amine in a lipid to form particles that can be used to encapsulate various drugs, especially chemotherapeutic agents
12/02/2004	US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes
12/02/2004	US20040241226 Administering a tyrosine kinase inhibitor, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured to presence of IL-3
12/02/2004	US20040241220 R(-)N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane; oral, transdermal, or injection drug delivery
12/02/2004	US20040241217 Method for administration of immune modulators in systemic and localized immune disorders
12/02/2004	US20040241204 Sustained release pharmaceutical composition
12/02/2004	US20040241171 Leukocyte inactivation module
12/02/2004	US20040241168 Compositions and methods for the treatment and clinical remission of psoriasis
12/02/2004	US20040241166 Use of inhibitors of ikk-beta and method for discovery of said inhibitors
12/02/2004	US20040241160 Vegfr-1 antibodies to treat breast cancer
12/02/2004	US20040241159 Serotonin receptor antagonists, analgesic (aspirin), and antiemitic; treating cephalic pain such as migraine, cluster headache, chronic paroxysmal hermicrania, headache associated with vascular disorders, headache associated with substances or their withdrawl, rebound headache and tension headache
12/02/2004	US20040241156 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
12/02/2004	DE10321725A1 Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke Enzyme-containing compositions, dietetic foods and medicines prepared therefrom and their use for medical purposes
12/02/2004	DE10061195B4 Verwendung von Abformmassen zur Herstellung von Behandlungsvorrichtungen Use of impression materials for the production of treatment devices
12/02/2004	CA2634766A1 Pharmaceutical composition containing histone deacetylase inhibitor
12/02/2004	CA2634765A1 Pharmaceutical composition containing histone deacetylase inhibitor
12/02/2004	CA2634709A1 Pharmaceutical composition containing histone deacetylase inhibitor
12/02/2004	CA2528521A1 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	CA2527191A1 Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent
12/02/2004	CA2526908A1 Combination of histone deacetylase inhibitors with chemotherapeutic agents
12/02/2004	CA2526349A1 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein
12/02/2004	CA2526278A1 Combination chemotherapy comprising a liposomal platinum complex
12/02/2004	CA2525946A1 Composition comprising a pde4 inhibitor and a pde5 inhibitor
12/02/2004	CA2525789A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
12/02/2004	CA2525696A1 Control of function of intracellular ca ion
12/02/2004	CA2525557A1 Methods for treating cancers using polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidene-2,6-dione
12/02/2004	CA2525280A1 Compositions for the treatment of reduced blood flow
12/02/2004	CA2525277A1 Method for augmenting the antitumor activity of anti-cancer agents
12/02/2004	CA2524870A1 Pharmaceutical combination comprising modafinil and another drug
12/02/2004	CA2524116A1 Antiarthritic combinations
12/02/2004	CA2521575A1 Antibiotic composition
12/02/2004	CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
12/02/2004	CA2431080A1 Enhancement of anticancer immunity through inhibition of arginase
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481678A1 Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
12/01/2004	EP1481675A1 Body temperature elevating agents
12/01/2004	EP1481673A1 Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
12/01/2004	EP1481672A1 Compositions for ameliorating fecal properties
12/01/2004	EP1481668A1 Use of anti-glaucoma drugs to treat visual field defects associated with the use of a GABAergic agent
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1481666A1 A composition for re-establishment of the vaginal ecosystem
12/01/2004	EP1481251A2 Estrogen receptor interaction with a transcription factor
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481093A2 MODULATION OF TYPE II&bgr; PHOSPHOINOSITIDE PHOSPHATE KINASE
12/01/2004	EP1481078A2 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
12/01/2004	EP1481077A2 Mitotic kinesin inhibitors
12/01/2004	EP1481065A2 Method for detection of leptin receptor ligands
12/01/2004	EP1481007A2 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
12/01/2004	EP1480982A2 Modified fluorinated nucleoside analogues
12/01/2004	EP1480976A1 Thiazole derivatives as npy receptor antagonists
12/01/2004	EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
12/01/2004	EP1480678A2 Treatment of ophthalmic disorders using urea and urea derivatives
12/01/2004	EP1480676A1 Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
12/01/2004	EP1480674A1 Treatment of central nervous system damage
12/01/2004	EP1480648A1 Anti-viral compounds
12/01/2004	EP1480646A1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
12/01/2004	EP1480639A1 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
12/01/2004	EP1480637A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
12/01/2004	EP1480636A2 Self emulsifying drug delivery systems for poorly soluble drugs
12/01/2004	EP1480634A2 Treating benign prostate hyperplasia with sarms
12/01/2004	EP1480630A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
12/01/2004	EP1480629A1 Combination therapy for treatment of schizophrenia
12/01/2004	EP1480628A1 Use of sodium/hydrogen exchange inhibitors for the treatment of thrombotic and inflammatory diseases
12/01/2004	EP1480627A1 Methods of reducing angiogenesis
12/01/2004	EP1480626A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity
12/01/2004	EP1480624A2 Pharmaceutical tablet
12/01/2004	EP1480623A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
12/01/2004	EP1480618A1 Sustained release drug formulations containing a carrier peptide
12/01/2004	EP1480616A1 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
12/01/2004	EP1480615A1 Formoterol superfine formulation
12/01/2004	EP1480613A1 Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
12/01/2004	EP1480514A2 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
12/01/2004	EP1261355B1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
12/01/2004	EP1212428B1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
12/01/2004	EP1183040B1 Therapeutic use of an inhibitor of a hedgehog signalling pathway
12/01/2004	EP1173197B1 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
12/01/2004	EP1073771B1 New method for the selection of clones of an expression library involving rearraying
12/01/2004	EP1059943B1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles
12/01/2004	EP1012180B1 Hepatitis c inhibitor peptide analogues
12/01/2004	EP0961610B1 Skin preparation
12/01/2004	EP0930076B1 Pharmaceutical compositions comprising CS-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
12/01/2004	CN1551877A Piperidine derivatives useful as CCR5 antagonists
12/01/2004	CN1551789A Single dose aromatase inhibitor for treating infertility

1 ... 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 ... 1151